Venture capital

China-US biotech startup raises money for flu drug

Lilly Asia Ventures, Oceanpine Capital, Matrix Partners China are betting on Ansun BioPharma to kill the virus on your respiratory tract.

China-US based biotech company Ansun BioPharma raised $80 million in its series B funding round to support the phase three clinical trial for its newly-developed medication, the company said on Monday

Oceanpine Capital led this round of fundraising Existing investors including Lilly Asia Ventures, Matrix Partners China, Yuanming Capital and other new investors joined this round of investment China Renaissance is the financial advisor of the deal

Ansun develops biologic drugs targeting viral respiratory tract infection It is in the process of developing a first-in-class medication, called DAS181, to cure lower respiratory infection caused by parainfluenza virus

Proceeds in the latest funding round will be used for the phase three clinical...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team subscription (2-5 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at [email protected], or +(852) 2122 5222